Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
Saved in:
| Title: | Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. |
|---|---|
| Authors: | Cannon CP (AUTHOR), Husted S (AUTHOR), Harrington RA (AUTHOR), Scirica BM (AUTHOR), Emanuelsson H (AUTHOR), Peters G (AUTHOR), Storey RF (AUTHOR), DISPERSE-2 Investigators (CORPORATE AUTHOR) |
| Source: | Journal of the American College of Cardiology (JACC). Nov2007, Vol. 50 Issue 19, p1844-1851. 8p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
